Compare Tata Nifty MidSmall Healthcare Index Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.12 | 1.86 |
NAV | ₹12.49 | ₹38.47 |
Fund Started | 08 Apr 2024 | 25 Jun 2018 |
Fund Size | ₹158.82 Cr | ₹6455.55 Cr |
Exit Load | Exit load of 0.25%, if redeemed within 15 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
1.12
1.86
NAV
₹12.49
₹38.47
Fund Started
08 Apr 2024
25 Jun 2018
Fund Size
₹158.82 Cr
₹6455.55 Cr
Exit Load
Exit load of 0.25%, if redeemed within 15 days.
Exit load of 1% if redeemed within 15 days.
1 Year | 5.06% | 1.79% |
3 Year | - | 26.35% |
5 Year | - | 16.49% |
1 Year
5.06%
1.79%
3 Year
-
26.35%
5 Year
-
16.49%
Equity | 100.06% | 97.87% |
Cash | -0.06% | 2.13% |
Equity
100.06%
97.87%
Cash
-0.06%
2.13%
Top 10 Holdings |
|
|
Top 10 Holdings
Lupin Ltd. | 9.51% |
Fortis Healthcare Ltd. | 8.56% |
Laurus Labs Ltd. | 8.00% |
Aurobindo Pharma Ltd. | 6.15% |
Alkem Laboratories Ltd. | 5.99% |
Glenmark Pharmaceuticals Ltd. | 5.70% |
Mankind Pharma Ltd. | 4.62% |
Biocon Ltd. | 4.40% |
Ipca Laboratories Ltd. | 3.67% |
Abbott India Ltd. | 2.82% |
Sun Pharmaceutical Industries Ltd. | 12.05% |
Cipla Ltd. | 7.90% |
Dr. Reddy's Laboratories Ltd. | 7.82% |
Divi's Laboratories Ltd. | 7.10% |
Mankind Pharma Ltd. | 6.44% |
Lupin Ltd. | 5.78% |
Aurobindo Pharma Ltd. | 5.19% |
Alkem Laboratories Ltd. | 3.66% |
Cohance Lifesciences Ltd. | 3.01% |
Syngene International Ltd. | 2.98% |
Name | - | - |
Start Date | - | - |
Name
-
-
Start Date
-
-
Description | The scheme seeks to provide returns, before expenses, that are in line with the performance of Nifty MidSmall Healthcare Index (TRI), subject to tracking error. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 08 Apr 2024 | 25 Jun 2018 |
Description
The scheme seeks to provide returns, before expenses, that are in line with the performance of Nifty MidSmall Healthcare Index (TRI), subject to tracking error.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
08 Apr 2024
25 Jun 2018